Results 71 to 80 of about 1,034,952 (285)

Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)

open access: yesPleura and Peritoneum, 2019
Background Peritoneal metastasis (PM) develop in more than 50 % of gastric cancer (GC) patients. Median survival without treatment is not more than 3–7 months, and 8–12 months after modern combination chemotherapy.
V. Khomyakov   +6 more
semanticscholar   +1 more source

Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

open access: yesAdvanced Science, EarlyView.
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng   +27 more
wiley   +1 more source

Adapting tumor interstitial fluid pressure for intraperitoneal chemotherapy [PDF]

open access: yes, 2014
C
Ceelen, Wim   +5 more
core   +1 more source

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

open access: yesIndian Journal of Anaesthesia, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide.
S. Solanki   +22 more
semanticscholar   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

open access: yesAdvanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan   +6 more
wiley   +1 more source

Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma

open access: yesAdvanced Science, EarlyView.
Molecular mechanism study of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in targeting MΦ reprogramming by regulating the CXCL12–CXCR4 signaling pathway to enhance immune recognition and clearance of GC (Created by BioRender). Abstract Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches.
Qianqian Cao   +9 more
wiley   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

open access: yesThe Lancet Oncology, 2021
F. Quénet   +16 more
semanticscholar   +1 more source

Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer

open access: yesCancer, 2019
Despite its widespread use, until recently, there was no randomized evidence for hyperthermic intraperitoneal chemotherapy (HIPEC) versus surgery without HIPEC for ovarian cancer.
I. Vergote, P. Harter, L. Chiva
semanticscholar   +1 more source

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu   +10 more
wiley   +1 more source

The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. [PDF]

open access: yes, 2017
The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing's sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to ...
Bouvet, Michael   +20 more
core   +1 more source

Home - About - Disclaimer - Privacy